Evolution and evidence-based adaptations in techniques for peroral endoscopic myotomy for achalasia - 14/07/22
Abstract |
Achalasia is an esophageal motility disorder characterized by impaired lower esophageal sphincter (LES) relaxation and failed peristalsis. Common clinical manifestations include dysphagia to solid and liquid foods, chest pain, regurgitation, and weight loss, resulting in significant morbidity and healthcare burden. Historically, surgical Heller myotomy and pneumatic dilation were the first-line therapeutic options for achalasia. This convention was shaken in 2009 when Inoue and colleagues introduced an endoscopic approach to dissect the muscle fibers of the LES, known as peroral endoscopic myotomy (POEM). Since incorporation of POEM into standard practice, the overall myotomy technique has remained unchanged; however, adaptations in the thickness and length of myotomy have evolved. Full-thickness myotomy is recognized to have similar clinical success and faster procedure times compared with selective circular muscle myotomy. Although myotomy length for type 1 and type 2 achalasia has classically been >6 cm, recent studies demonstrated similar outcomes with reduction of myotomy length to <3 cm. Length of myotomy for type 3 achalasia has been tailored to treat the entire length of spastic muscle segment, and the modality to gauge the optimal thickness and length of myotomy in this group has yet to be established. In addition to changes in POEM technique, the postoperative management of POEM has also changed, favoring reduced postprocedure imaging, antibiotic use, and hospitalizations.
Le texte complet de cet article est disponible en PDF.Abbreviations : DI, FLIP, GEJ, HM, HRM, LES, POEM
Plan
| DISCLOSURE: The following authors received research support for this study from the National Institutes of Health: E. E. Low (T32 grant; 5T32DK007202-44), R. Yadlapati (K23 DK125266). In addition, the following authors disclosed financial relationships: S. A. Fehmi: Consultant for Cook Medical and Boston Scientific. R. Yadlapati: Consultant for Medtronic, Phathom Pharmaceuticals, and StatLinkMD; research support from Ironwood Pharmaceuticals; advisory board member with stock options for RJS Mediagnostix. All other authors disclosed no financial relationships. |
Vol 96 - N° 2
P. 189-196 - août 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
